#biotech

🏢Release 📈 Stocks

Genezen Partners With InterAct Therapeutics to Advance AAV8 Gene Therapy

October 5, 2026 (36 days ago)

Genezen expands its CDMO pipeline through a new partnership with InterAct Therapeutics, aiming to scale manufacturing for advanced AAV8-based anti-metastasis gene therapies.

Genezen

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

PMV Pharmaceuticals Appoints Healthcare Investor Eckler to Board

October 5, 2026 (36 days ago)

PMV Pharmaceuticals adds veteran investor Dr. Eckler to its board, bringing over 20 years of expertise from firms like Samsara BioCapital and…

PMVP

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

TuHURA Biosciences Secures U.S. Patent for DOR ADC Technology Platform

October 5, 2026 (36 days ago)

TuHURA Biosciences strengthens its intellectual property portfolio with a new U.S. patent covering its DOR ADC platform, expanding potential applications into CAR-T…

HURA

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

CSL Partners With Alentis in $1.55 Billion Rare Disease Drug Deal

October 5, 2026 (36 days ago)

CSL secures global rights to Alentis Therapeutics' lixudebart in a deal worth up to US$1.55 billion, marking a major expansion of its…

CSL Alentis Therapeutics

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

NeuroSense Therapeutics Regains Nasdaq Minimum Bid Price Compliance

October 2, 2026 (38 days ago)

NeuroSense Therapeutics satisfies Nasdaq's minimum bid price rule while seeking a hearing to address ongoing market value compliance requirements.

NRSN

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Eli Lilly Gains FDA Approval for Jaypirca to Treat CLL and SLL Patients

October 2, 2026 (38 days ago)

Eli Lilly expands its oncology footprint as the FDA approves Jaypirca for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,…

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

PhytoHealth CEO Receives Industry Award for PG2 Cancer Fatigue Drug

October 2, 2026 (39 days ago)

PhytoHealth CEO Angel Lee earns industry recognition for the development of PG2, a breakthrough botanical treatment for cancer-related fatigue, bolstering the company's…

4128.TW

🌍 ASIA Read More →

🏢Release 📈 Stocks

ABK Biomedical Breaks Ground on New Missouri Facility for Cancer Treatment

October 2, 2026 (39 days ago)

ABK Biomedical kicks off construction of a new Missouri-based facility, partnering with local academic and construction leaders to accelerate the development of…

ABK Biomedical Inc.

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

miRoncol Health Launches Canada's First miRNA Multi-Cancer Screening Test

October 1, 2026 (40 days ago)

miRoncol Health introduces miCheckup, a novel miRNA-based blood test designed to detect early-stage cancer signals, expanding the landscape of Canadian diagnostic screening…

miRoncol Health

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Achieve Life Sciences Appoints New CFO to Lead Cytisinicline Commercialization

October 1, 2026 (40 days ago)

Achieve Life Sciences strengthens its executive suite with a new CFO appointment, signaling a strategic focus on the upcoming commercialization phase for…

ACHV

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

ZYUS Life Sciences Reports Positive Phase 2a Results for Trichomylin

October 1, 2026 (40 days ago)

ZYUS Life Sciences shares gain momentum as Phase 2a UTOPIA-1 trial data confirms Trichomylin efficacy and safety for cancer pain management.

ZYUS

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Lutris Pharma Reports 71.8% Success Rate in Phase 2 LUT014 Gel Trial

October 1, 2026 (40 days ago)

Lutris Pharma shares gain momentum after reporting that its LUT014 0.1% gel significantly outperformed placebo in Phase 2 trials, achieving a 71.8%…

Lutris Pharma

🌍 AMERICAS Read More →